356 related articles for article (PubMed ID: 11125382)
1. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Heidenreich A; Hofmann R; Engelmann UH
J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
[TBL] [Abstract][Full Text] [Related]
2. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract][Full Text] [Related]
3. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
[TBL] [Abstract][Full Text] [Related]
4. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
Ozyuvaci E; Altan A; Demir C
Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
6. [Clodronate in the palliative therapy of bone-metastasized prostatic carcinoma].
Vorreuther R; Klotz T; Engelking R
Urologe A; 1992 Mar; 31(2):63-6. PubMed ID: 1373255
[TBL] [Abstract][Full Text] [Related]
7. Ibandronate in the treatment of prostate cancer associated painful osseous metastases.
Heidenreich A; Elert A; Hofmann R
Prostate Cancer Prostatic Dis; 2002; 5(3):231-5. PubMed ID: 12496987
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
[TBL] [Abstract][Full Text] [Related]
9. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hormone-refractive prostatic carcinoma with painful bone metastasis. Epirubicin vs. clodronate vs. epirubicin plus clodronate].
Heidenreich A
Urologe A; 1997 Nov; 36(6):568. PubMed ID: 9487597
[No Abstract] [Full Text] [Related]
11. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
[TBL] [Abstract][Full Text] [Related]
12. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
[TBL] [Abstract][Full Text] [Related]
13. Clodronate in the management of bone metastases: a clinical study of 91 patients.
Serkies K; Jereczek-Fossa B; Badzio A; Jassem J
Neoplasma; 1999; 46(5):317-22. PubMed ID: 10665850
[TBL] [Abstract][Full Text] [Related]
14. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer and bone metastases. The effect of clodronate.
Kylmälä T
Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
[No Abstract] [Full Text] [Related]
17. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
[TBL] [Abstract][Full Text] [Related]
18. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
[TBL] [Abstract][Full Text] [Related]
19. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population.
Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D
Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
